POLIMORFISME CYP2C19*2 TERHADAP AGREGASI PLATELET DAN KEJADIAN KARDIOVASKULAR PADA PASIEN PENYAKIT JANTUNG KORONER

Coronary Heart Disease (CHD) is a cardiovascular disease that can caused by the presence of coronary artery plaque blockage. Clopidogrel one antiplatelet therapy in CHD patients. CYP2C19 *2 polymorphisms reduce effectiveness clopidogrel active metabolites. This research was conducted at RSUD Sidoarjo East Java from November to December 2017continued monitoring events March 2018. The method used Polymerase Chain Reaction (PCR) and Light Transmittance Aggregometry (LTA) for platelet aggregation measurement. From 25 sample inclusion,there are wild type alleles (bp values ​​around 120 bp; 1 patient), homozygous 169 18 patients) allele heterozygotes 120bp, 169bp; 6 patients). most common polymorphism homozygotes. There patient hyperaggregation after being monitored 3 months. Analysis relationship between CYP2C19*2 genetic with events, using kruskal wallis test. result no significant (p=0.512), as well did not make any difference which also (p=0.426). results association showed differences (p=0.027).